AbbVie's neuroscience portfolio now contributes over 17% of total company revenues, driven by double-digit growth in key brands. Botox sales increased 12% year-over-year, propelling cosmetic and therapeutic revenues, while Vraylar prescriptions surged 28% as the atypical antipsychotic gained market share in bipolar disorder and schizophrenia. Migraine treatment Imbruvica reported a 23% uplift in U.S. prescriptions, reflecting expanded patient access following recent label expansions. Collectively, these therapies offset slower growth in established immunology products and underpin AbbVie’s strategy to diversify beyond its core rheumatoid arthritis franchise.

Analysts maintain a Moderate Buy consensus on AbbVie, with an average price target implying a 10% upside from current levels. The stock trades at a forward P/E multiple of approximately 14.4x projected 2027 earnings, below the industry average of 16x, reflecting investor confidence in AbbVie’s pipeline and free cash flow generation. Consensus models forecast adjusted EPS of $12.31 for fiscal 2026, up 9% from 2025, driven by continued ramp-up of Skyrizi and Rinvoq in immunology. Technical indicators suggest a bullish breakout if shares clear resistance near year-to-date highs, reinforcing a GARP (growth at a reasonable price) thesis for patient investors.

During the third quarter, Generali Asset Management SPA SGR trimmed its stake by 7.3%, selling 6,172 shares and ending the period with 78,122 shares held, representing roughly $18 million in market value. In contrast, Banque Pictet & Cie SA boosted its holdings by 89.2%, acquiring an additional 157,480 shares to reach a position valued at $77.3 million. Together with Norges Bank’s new $4.29 billion position and Vanguard’s incremental 1.9% increase, institutional ownership stands at over 70%, underscoring confidence in AbbVie’s cash flow profile and near-term growth catalysts.